MDT

87.68

-0.25%↓

A

115.21

-1.4%↓

VEEV

158.09

-9.21%↓

HQY

81.91

+0.33%↑

TLRY

6.61

-2.94%↓

MDT

87.68

-0.25%↓

A

115.21

-1.4%↓

VEEV

158.09

-9.21%↓

HQY

81.91

+0.33%↑

TLRY

6.61

-2.94%↓

MDT

87.68

-0.25%↓

A

115.21

-1.4%↓

VEEV

158.09

-9.21%↓

HQY

81.91

+0.33%↑

TLRY

6.61

-2.94%↓

MDT

87.68

-0.25%↓

A

115.21

-1.4%↓

VEEV

158.09

-9.21%↓

HQY

81.91

+0.33%↑

TLRY

6.61

-2.94%↓

MDT

87.68

-0.25%↓

A

115.21

-1.4%↓

VEEV

158.09

-9.21%↓

HQY

81.91

+0.33%↑

TLRY

6.61

-2.94%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

75.28 0.35

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.12

Max

75.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+31.53% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.4B

12B

Ankstesnė atidarymo kaina

74.93

Ankstesnė uždarymo kaina

75.28

Naujienos nuotaikos

By Acuity

50%

50%

168 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-08 20:44; UTC

Uždarbis

Costco Reports 11% Growth in March Sales

2026-04-08 23:51; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-08 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

2026-04-08 23:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-04-08 22:56; UTC

Rinkos pokalbiai

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

2026-04-08 22:45; UTC

Rinkos pokalbiai

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

2026-04-08 22:17; UTC

Rinkos pokalbiai

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

2026-04-08 21:52; UTC

Svarbiausios naujienos

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

2026-04-08 21:24; UTC

Uždarbis

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

2026-04-08 21:01; UTC

Svarbiausios naujienos

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

2026-04-08 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-08 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

2026-04-08 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

2026-04-08 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

2026-04-08 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

2026-04-08 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

2026-04-08 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Responds to TRC Cap Mini-Tender Offer

2026-04-08 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-08 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

2026-04-08 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

2026-04-08 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

2026-04-08 19:44; UTC

Uždarbis

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

2026-04-08 19:16; UTC

Rinkos pokalbiai

Hogs Follow Cutout Prices Lower -- Market Talk

2026-04-08 19:02; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-08 19:02; UTC

Rinkos pokalbiai

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

2026-04-08 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

2026-04-08 18:51; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-08 18:51; UTC

Rinkos pokalbiai

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

2026-04-08 18:14; UTC

Svarbiausios naujienos

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

2026-04-08 18:05; UTC

Svarbiausios naujienos

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

31.53% į viršų

12 mėnesių prognozė

Vidutinis 97.19 USD  31.53%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

168 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat